MX2010004164A - Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma. - Google Patents

Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.

Info

Publication number
MX2010004164A
MX2010004164A MX2010004164A MX2010004164A MX2010004164A MX 2010004164 A MX2010004164 A MX 2010004164A MX 2010004164 A MX2010004164 A MX 2010004164A MX 2010004164 A MX2010004164 A MX 2010004164A MX 2010004164 A MX2010004164 A MX 2010004164A
Authority
MX
Mexico
Prior art keywords
antibody
type
proteasome inhibitor
combination therapy
combination
Prior art date
Application number
MX2010004164A
Other languages
English (en)
Inventor
Georg Fertig
Pablo Umana
Thomas Friess
Christian Klein
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2010004164A publication Critical patent/MX2010004164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un anticuerpo anti-CD20 de tipo II para la fabricación de un medicamento destinado al tratamiento del cáncer, en especial de un cáncer que exprese al CD2O, en combinación con un inhibidor de proteasoma.
MX2010004164A 2007-10-24 2008-10-22 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma. MX2010004164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07020820 2007-10-24
PCT/EP2008/008919 WO2009053038A2 (en) 2007-10-24 2008-10-22 Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor

Publications (1)

Publication Number Publication Date
MX2010004164A true MX2010004164A (es) 2010-08-04

Family

ID=38973774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004164A MX2010004164A (es) 2007-10-24 2008-10-22 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.

Country Status (16)

Country Link
US (4) US20090110688A1 (es)
EP (1) EP2205318B1 (es)
JP (1) JP5469073B2 (es)
KR (1) KR101280733B1 (es)
AR (1) AR071733A1 (es)
AU (1) AU2008315926A1 (es)
CA (1) CA2702962C (es)
CL (1) CL2008003122A1 (es)
ES (1) ES2527775T3 (es)
IL (1) IL205025A0 (es)
MX (1) MX2010004164A (es)
PE (1) PE20090975A1 (es)
RU (1) RU2520757C2 (es)
TW (1) TW200927762A (es)
WO (1) WO2009053038A2 (es)
ZA (1) ZA201002575B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58420B1 (sr) 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2011018225A1 (en) * 2009-08-14 2011-02-17 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2498793B1 (en) * 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
CA2795544A1 (en) * 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
US8809282B2 (en) * 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
TW201208703A (en) * 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
CN103261229A (zh) * 2010-12-16 2013-08-21 罗切格利卡特公司 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
CA2834680A1 (en) * 2011-04-29 2012-11-01 Emory University Selecting use of proteasome inhibitors based on nf-kb2 sequence
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
CA2862320A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
KR102127085B1 (ko) 2013-03-13 2020-06-26 제넨테크, 인크. 항체 제제
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
PT1071700E (pt) * 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CN1407901A (zh) * 1999-11-08 2003-04-02 Idec药物公司 使用抗cd40l抗体并联合抗cd20抗体和/或化疗剂和放疗治疗b细胞恶性瘤
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
RS58420B1 (sr) * 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
KR20080031001A (ko) * 2005-06-02 2008-04-07 아스트라제네카 아베 Ｃｄ20에 대한 항체 및 그의 용도
BRPI0615397B1 (pt) * 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo

Also Published As

Publication number Publication date
WO2009053038A3 (en) 2009-06-25
WO2009053038A2 (en) 2009-04-30
CL2008003122A1 (es) 2009-10-16
AU2008315926A1 (en) 2009-04-30
CN102083499A (zh) 2011-06-01
RU2010120724A (ru) 2012-05-20
CA2702962A1 (en) 2009-04-30
KR20100068292A (ko) 2010-06-22
US20090110688A1 (en) 2009-04-30
ES2527775T3 (es) 2015-01-29
AR071733A1 (es) 2010-07-14
KR101280733B1 (ko) 2013-07-02
CA2702962C (en) 2016-10-25
EP2205318A2 (en) 2010-07-14
US20120219549A1 (en) 2012-08-30
JP2011500741A (ja) 2011-01-06
JP5469073B2 (ja) 2014-04-09
TW200927762A (en) 2009-07-01
RU2520757C2 (ru) 2014-06-27
IL205025A0 (en) 2010-11-30
ZA201002575B (en) 2011-04-28
US20110200598A1 (en) 2011-08-18
PE20090975A1 (es) 2009-07-13
US20160000912A1 (en) 2016-01-07
EP2205318B1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
MX355849B (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina.
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX352738B (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MY181960A (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
AU2012335543A8 (en) HER3 antibodies and uses thereof
MX342590B (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
NZ736727A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
MX2020001727A (es) Terapia de combinacion.
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
NZ607472A (en) Treatment for neoplastic diseases
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
UA99934C2 (ru) Лечение рака молочной железы с помощью соединения 4-йодо-3-нитробензамида в комбинации с противоопухолевыми средствами

Legal Events

Date Code Title Description
FG Grant or registration